tiprankstipranks
Advertisement
Advertisement

HK:0013 Stock Latest News

HUTCHMED Showcases Broad Oncology Pipeline With New Data at 2026 ASCO Meeting
Company AnnouncementsHUTCHMED Showcases Broad Oncology Pipeline With New Data at 2026 ASCO Meeting
1d ago
Hutchmed, Innovent jointly announce NMPA approval for Elunate/Tyvyt combination
PremiumThe Fly
Hutchmed, Innovent jointly announce NMPA approval for Elunate/Tyvyt combination
2d ago
HCM
Hutchmed, Innovent Biologics announce China NMPA approval for NDA
PremiumThe Fly
Hutchmed, Innovent Biologics announce China NMPA approval for NDA
2d ago
HCM
HUTCHMED–Innovent Combo Wins China Nod for Advanced Kidney Cancer
PremiumCompany Announcements
HUTCHMED–Innovent Combo Wins China Nod for Advanced Kidney Cancer
2d ago
HUTCHMED shareholders approve all resolutions at 2026 AGM
PremiumCompany Announcements
HUTCHMED shareholders approve all resolutions at 2026 AGM
11d ago
HUTCHMED Confirms Total Voting Rights and Share Capital Structure
PremiumCompany AnnouncementsHUTCHMED Confirms Total Voting Rights and Share Capital Structure
23d ago
Hutchmed says NDA for sovleplenib accepted in China
Premium
The Fly
Hutchmed says NDA for sovleplenib accepted in China
24d ago
HCM
HUTCHMED Wins Priority Review in China for Sovleplenib in Autoimmune Anemia
Premium
Company Announcements
HUTCHMED Wins Priority Review in China for Sovleplenib in Autoimmune Anemia
24d ago
HUTCHMED Publishes 2025 Annual Report and Sets Hybrid 2026 AGM
PremiumCompany Announcements
HUTCHMED Publishes 2025 Annual Report and Sets Hybrid 2026 AGM
1M ago
HUTCHMED Sets 2026 AGM With New Share Issuance and Buyback Mandates
PremiumCompany Announcements
HUTCHMED Sets 2026 AGM With New Share Issuance and Buyback Mandates
1M ago
HUTCHMED to Unveil New ATTC and Surufatinib Data at AACR 2026
PremiumCompany Announcements
HUTCHMED to Unveil New ATTC and Surufatinib Data at AACR 2026
1M ago
HUTCHMED Launches Phase III Trial of BTK Inhibitor HMPL-760 in Chinese Lymphoma Patients
PremiumCompany Announcements
HUTCHMED Launches Phase III Trial of BTK Inhibitor HMPL-760 in Chinese Lymphoma Patients
2M ago
HUTCHMED CEO’s Long-Term Incentive Share Awards Vest
PremiumCompany AnnouncementsHUTCHMED CEO’s Long-Term Incentive Share Awards Vest
2M ago
HUTCHMED Vests 726,317 LTIP Shares to Top Executives After 2025 Results
Premium
Company Announcements
HUTCHMED Vests 726,317 LTIP Shares to Top Executives After 2025 Results
2M ago
Hutchmed price target lowered to $20 from $21 at BofA
Premium
The Fly
Hutchmed price target lowered to $20 from $21 at BofA
2M ago
HCM
Hutchmed discontinues all active tazemetostat clinical trials
PremiumThe Fly
Hutchmed discontinues all active tazemetostat clinical trials
3M ago
HCM
HUTCHMED to Withdraw Cancer Drug TAZVERIK in Greater China After Ipsen Safety Move
PremiumCompany Announcements
HUTCHMED to Withdraw Cancer Drug TAZVERIK in Greater China After Ipsen Safety Move
3M ago
Hutchmed price target lowered to $21 from $22 at BofA
PremiumThe Fly
Hutchmed price target lowered to $21 from $22 at BofA
3M ago
HCM
HUTCHMED reshapes board leadership as veteran independent director plans retirement
PremiumCompany Announcements
HUTCHMED reshapes board leadership as veteran independent director plans retirement
3M ago
HUTCHMED Publishes 2025 Form 20-F for Investors
PremiumCompany AnnouncementsHUTCHMED Publishes 2025 Form 20-F for Investors
3M ago
HUTCHMED Posts Strong 2025 Profit as ATTC Pipeline and Global Oncology Portfolio Advance
Premium
Company Announcements
HUTCHMED Posts Strong 2025 Profit as ATTC Pipeline and Global Oncology Portfolio Advance
3M ago
HUTCHMED launches global early-stage trial for novel ATTC cancer therapy HMPL-A580
Premium
Company Announcements
HUTCHMED launches global early-stage trial for novel ATTC cancer therapy HMPL-A580
3M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >